<DOC>
	<DOCNO>NCT01428388</DOCNO>
	<brief_summary>Antagonists vascular endothelial growth factor ( VEGF ) pathway effective treat macular edema result retinal vein occlusion ( RVO ) . In eye , two widely use anti-VEGF agent ranibizumab bevacizumab . Only ranibizumab FDA-approved treatment macular edema RVO , however bevacizumab use off-label many ophthalmologist good success . Furthermore , cost bevacizumab less one-tenth cost ranibizumab . Here investigator conduct six month randomize , prospective interventional trial compare effectiveness ranibizumab bevacizumab treatment macular edema RVO . Primary outcome measure change central retinal thickness . Secondary measure change visual acuity baseline change angiographic property macular lesion baseline treatment .</brief_summary>
	<brief_title>Bevacizumab Versus Ranibizumab Treatment Macular Edema From Vein Occlusion</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>Ability provide inform consent Visual acuity 20/40 20/320 study eye ( regardless relative APD ) Central foveal thickness ( CFT ) &gt; 250 micron assess OCT ( see ) Diagnosis retinal vein occlusion past 9 month Age 50 year History previous intraocular surgery study eye , include par plana vitrectomy ( include uncomplicated cataract surgery ) , within 60 day screen visit Inability make study visit Uncontrolled glaucoma study eye ( defined intraocular pressure ( IOP ) â‰¥ 25 mmHg ) despite treatment two topical pharmacological antiglaucomatous medication ) Pregnancy lactation Evidence diabetic retinopathy exam history diabetic macular edema within 12 week study onset Any intravitreal injection within 12 week study onset Prior retinal vein occlusion History panretinal photocoagulation within 3 month study onset anticipate within 4 month study onset History cerebrovascular event myocardial infarction within 3 month study onset</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>macular edema</keyword>
	<keyword>vein occlusion</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>vascular endothelial growth factor</keyword>
</DOC>